14521-98-3 Usage
Uses
Used in Pharmaceutical Industry:
Hydrocodone is used as a prescription pain medication for the management of moderate to severe pain. Its opioid receptor binding properties allow it to provide effective analgesia, making it a valuable component in pain management regimens.
Used as a Cough Suppressant:
In addition to its pain-relieving properties, hydrocodone is also used as a cough suppressant. Its action on the central nervous system helps to reduce the urge to cough, providing relief for individuals suffering from persistent coughing.
Used in Controlled Substance Regulation:
Due to its high potential for abuse and the risk of physical dependence, hydrocodone is classified as a Schedule II controlled substance in the United States. This classification ensures that it is only available through a prescription from a qualified healthcare provider, helping to mitigate the risk of misuse and overdose.
Check Digit Verification of cas no
The CAS Registry Mumber 14521-98-3 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,4,5,2 and 1 respectively; the second part has 2 digits, 9 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 14521-98:
(7*1)+(6*4)+(5*5)+(4*2)+(3*1)+(2*9)+(1*8)=93
93 % 10 = 3
So 14521-98-3 is a valid CAS Registry Number.
InChI:InChI=1/C30H35NO4/c1-27(33,12-11-19-7-5-4-6-8-19)22-18-28-13-14-30(22,34-3)26-29(28)15-16-31(2)23(28)17-20-9-10-21(32)25(35-26)24(20)29/h4-10,13-14,22-23,26,32-33H,11-12,15-18H2,1-3H3/t22-,23-,26-,27-,28-,29+,30-/m1/s1
14521-98-3Relevant academic research and scientific papers
Synthesis and evaluation of a full-agonist orvinol for PET-imaging of opioid receptors: [11C]PEO
Marton, János,Schoultz, Bent W.,Hjoernevik, Trine,Drzezga, Alexander,Yousefi, Behrooz H.,Wester, Hans-Jurgen,Willoch, Frode,Henriksen, Gjermund
supporting information; experimental part, p. 5586 - 5589 (2010/03/24)
Antagonist radiotracers have shown only a low sensitivity for detecting competition from high-efficacy agonists at opioid receptors (ORs) in vivo. We report that [11C]PEO binds with high affinity to μ and κ-opioid receptors, is a full agonist, and concentrates in brain regions of rats with a high density of the μ-OR after intravenous injection. Blocking studies with μ and κ-OR selective compounds demonstrated that the binding of [11C]PEO is saturable and selective to the μ-OR in rat brain.
